Altering the Anti-inflammatory Lipoxin Microenvironment: a New Insight into Kaposi's Sarcoma-Associated Herpesvirus Pathogenesis.
Lipoxins are host anti-inflammatory molecules that play a vital role in restoring tissue homeostasis. The efficacy of lipoxins and their analog epilipoxins in treating inflammation and its associated diseases has been well documented. Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL) are two well-known inflammation related diseases caused by Kaposi's sarcoma-associated herpesvirus (KSHV). Controlling inflammation is one of the strategies adopted to treat KS and PEL, a primary motivation for exploring and evaluating the therapeutic potential of using lipoxins. This study documents how KSHV manipulates and downregulates the secretion of the anti-inflammatory lipoxin A4 in host cells and the viral factors involved in this process using in vitro KS and PEL cells as models. The presence of the lipoxin A4 receptor/formyl peptidyl receptor (ALX/FPR) in KS patient tissue sections and in vitro KS and PEL cell models offers a novel possibility for treating KS and PEL with lipoxins. Treating de novo KSHV-infected endothelial cells with lipoxin and epilipoxin creates an anti-inflammatory environment by decreasing the levels of NF-κB, AKT, ERK1/2, COX-2, and 5-lipoxygenase. Lipoxin treatment on CRISPR/CAS9 technology-mediated ALX/FPR gene deletion revealed the importance of the lipoxin receptor ALX for effective lipoxin signaling. A viral microRNA (miRNA) cluster was identified as the primary factor contributing to the downregulation of lipoxin A4 secretion in host cells. The KSHV miRNA cluster probably targets enzyme 15-lipoxygenase, which is involved in lipoxin A4 synthesis. This study provides a new insight into the potential treatment of KS and PEL using nature's own anti-inflammatory molecule, lipoxin.


OBJECTIVE
KSHV infection has been shown to upregulate several host proinflammatory factors, which aid in its survival and pathogenesis. The influence of KSHV infection on anti-inflammatory molecules is not well studied. Since current treatment methods for KS and PEL are fraught with unwanted side effects and low efficiency, the search for new therapeutics is therefore imperative. The use of nature's own molecule lipoxin as a drug is promising. This study opens up new domains in KSHV research focusing on how the virus modulates lipoxin secretion and warrants further investigation of the therapeutic potential of lipoxin using in vitro cell models for KS and PEL.
H. M. Bligh Cancer Research Laboratories, Department of Microbiology and Immunology, North Chicago, Illinois, USA.
Jayashree A
JA
Chandrasekharan
Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA.
Xiao M
XM
Huang
Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA.
Alexander C
AC
Hwang
H. M. Bligh Cancer Research Laboratories, Department of Microbiology and Immunology, North Chicago, Illinois, USA neelam.sharma-walia@rosalindfranklin.edu.|Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, USA.
Neelam
N
Sharma-Walia
D048868:Adaptor Proteins, Signal Transducing / Q000172:deficiency / Q000235:genetics / Q000276:immunology*; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001094:Arachidonate 5-Lipoxygenase / Q000235:genetics / Q000276:immunology; D064113:CRISPR-Cas Systems; D002460:Cell Line; D051546:Cyclooxygenase 2 / Q000235:genetics / Q000276:immunology; D042783:Endothelial Cells / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D005786:Gene Expression Regulation; D019288:Herpesvirus 8, Human / Q000235:genetics / Q000276:immunology / Q000472:pathogenicity*; D054884:Host-Pathogen Interactions; D006801:Humans; D007249:Inflammation; D044045:Lipoxins / Q000494:pharmacology*; D054685:Lymphoma, Primary Effusion / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000821:virology; D035683:MicroRNAs / Q000235:genetics / Q000276:immunology; D019950:Mitogen-Activated Protein Kinase 1 / Q000235:genetics / Q000276:immunology; D048052:Mitogen-Activated Protein Kinase 3 / Q000235:genetics / Q000276:immunology; D016328:NF-kappa B / Q000235:genetics / Q000276:immunology; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics / Q000276:immunology; D012367:RNA, Viral / Q000235:genetics / Q000276:immunology; D012514:Sarcoma, Kaposi / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000821:virology; D015398:Signal Transduction
D048868:Adaptor Proteins, Signal Transducing; D000893:Anti-Inflammatory Agents; C442142:HSH2D protein, human; D044045:Lipoxins; D035683:MicroRNAs; D016328:NF-kappa B; D012367:RNA, Viral; C040527:lipoxin A4; D001094:Arachidonate 5-Lipoxygenase; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D051057:Proto-Oncogene Proteins c-akt; C535150:MAPK1 protein, human; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3
J Virol. 2007 Apr;81(8):3949-68
17287275
J Virol. 1997 Jan;71(1):715-9
8985403
Viruses. 2016 Feb 19;8(2):null
26907327
PLoS Pathog. 2011 Dec;7(12):e1002405
22174674
J Clin Virol. 2000 May;16(3):203-13
10738139
FASEB J. 2010 Nov;24(11):4240-9
20570963
J Virol. 2001 Jan;75(2):891-902
11134302
J Virol. 2003 Jan;77(2):1524-39
12502866
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4546-51
10200299
Ernst Schering Res Found Workshop. 2000;(31):143-85
10943332
PLoS Pathog. 2010 Feb 12;6(2):e1000777
20169190
J Virol. 2004 Apr;78(8):4207-23
15047836
J Virol. 2005 Jul;79(14):9301-5
15994824
Biotechnol Bioeng. 2015 May;112(5):1060-4
25362885
J Skin Cancer. 2014;2014:246076
24701351
Oncogenesis. 2012 Apr 02;1:e5
23552603
Nat Methods. 2005 Apr;2(4):269-76
15782219
Nucleic Acids Res. 2015 Nov 16;43(20):e134
26130722
Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5570-5
15800047
Mol Neurobiol. 2014 Aug;50(1):97-106
24293102
Cancer Res. 2004 Jan 1;64(1):72-84
14729610
PLoS Pathog. 2009 Mar;5(3):e1000324
19266083
FASEB J. 2011 Dec;25(12):4326-37
21885654
Proc Natl Acad Sci U S A. 1984 Sep;81(17):5335-9
6089195
Cancer Lett. 2011 Jun 28;305(2):150-62
21377267
Virus Genes. 2009 Apr;38(2):195-203
19139983
Rheum Dis Clin North Am. 2004 Feb;30(1):69-95
15061569
Cell Host Microbe. 2008 Jan 17;3(1):1-3
18191785
N Engl J Med. 2003 Apr 24;348(17):1681-91
12711744
Transl Res. 2013 Aug;162(2):77-92
23567332
Cell Host Microbe. 2009 Dec 17;6(6):570-5
20006845
J Virol. 2014 Feb;88(4):2131-56
24335295
Br J Pharmacol. 2008 Mar;153 Suppl 1:S200-15
17965751
J Virol. 2006 Jun;80(11):5371-82
16699017
J Am Soc Nephrol. 2002 Oct;13(10):2497-507
12239238
J Virol. 1998 Oct;72(10):8309-15
9733875
Am J Pathol. 2001 Jan;158(1):3-9
11141472
J Virol. 2005 Aug;79(16):10308-29
16051824
Cell. 2004 Jan 23;116(2):281-97
14744438
Br J Pharmacol. 2009 Oct;158(4):947-59
19785661
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a001651
20457564
AIDS Res Hum Retroviruses. 2001 Jan 1;17(1):35-43
11177381
Cell Host Microbe. 2011 Nov 17;10(5):515-26
22100165
Nat Biotechnol. 2014 Apr;32(4):347-55
24584096
Biochemistry. 1999 Jun 8;38(23 ):7594-600
10360957
Mol Cancer Ther. 2007 Aug;6(8):2360-70
17699731
Biomed Res Int. 2014;2014:436097
24800225
Transl Res. 2013 Jun;161(6):447-68
23523954
Front Immunol. 2013 Jan 07;3:401
23316192
Viruses. 2014 Nov 24;6(11):4731-59
25421895
Cancer Res. 2007 May 1;67(9):4042-51
17483315
Adv Cancer Res. 1999;76:121-60
10218100
Science. 2013 Feb 15;339(6121):823-6
23287722
Transl Res. 2015 Aug;166(2):111-33
25814167
Viruses. 2014 Oct 23;6(10):4024-46
25341665
J Clin Invest. 2007 Apr;117(4):1019-28
17364023
Cancer Res. 2010 May 1;70(9):3697-708
20388794
Future Microbiol. 2010 Sep;5(9):1349-65
20860481
J Inflamm Res. 2015 Sep 30;8:181-92
26457057
Oncologist. 2007 May;12(5):569-76
17522245
Prostaglandins Leukot Essent Fatty Acids. 2008 Sep-Nov;79(3-5):157-63
19008087
J Virol. 2006 Jul;80(13):6534-52
16775340